Senti Biosciences to Present at H.C. Wainwright Global Investment Conference
ByAinvest
Tuesday, Sep 2, 2025 9:11 am ET1min read
SNTI--
Dr. Lu will discuss Senti Biosciences' proprietary Gene Circuit platform and its clinical-stage cell and gene therapies. The Gene Circuit platform is designed to engineer new medicines with enhanced precision and control, capable of precisely killing cancer cells while sparing healthy cells and increasing specificity to target tissues. Senti Bio's pipeline includes cell therapies engineered with Gene Circuits to target challenging liquid and solid tumor indications. The platform has been shown preclinically to work in both NK and T cells and has demonstrated potential in other modalities and diseases outside of oncology.
In addition to the presentation, Senti Bio's management will be available for one-on-one meetings with qualified investors attending the conference. A live video webcast of the presentation will be available on Senti Bio's website, with a replay archived for 90 days following the event.
For more information about the conference, interested parties can visit the conference website. Additional information about Senti Bio can be found on the company's website, [Senti Bio](https://www.sentibio.com), or by following the company on X (@SentiBio) and LinkedIn (Senti Biosciences).
References:
[1] https://www.stocktitan.net/news/SNTI/senti-bio-to-present-at-the-h-c-wainwright-27th-annual-global-h01iszlz6505.html
[2] https://finance.yahoo.com/news/senti-bio-present-h-c-130500881.html
Senti Biosciences announced that Timothy Lu, CEO, will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025. Lu will discuss the company's Gene Circuit platform and its clinical-stage cell and gene therapies. The presentation will be available as a live webcast on Senti Bio's website, with a replay available for 90 days.
Senti Biosciences, Inc. (Nasdaq: SNTI), a clinical-stage biotechnology company focused on developing next-generation cell and gene therapies, has announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference. The event will take place on September 8, 2025, in New York, NY, with a presentation by Co-Founder and CEO Dr. Timothy Lu scheduled for 2:00 PM ET.Dr. Lu will discuss Senti Biosciences' proprietary Gene Circuit platform and its clinical-stage cell and gene therapies. The Gene Circuit platform is designed to engineer new medicines with enhanced precision and control, capable of precisely killing cancer cells while sparing healthy cells and increasing specificity to target tissues. Senti Bio's pipeline includes cell therapies engineered with Gene Circuits to target challenging liquid and solid tumor indications. The platform has been shown preclinically to work in both NK and T cells and has demonstrated potential in other modalities and diseases outside of oncology.
In addition to the presentation, Senti Bio's management will be available for one-on-one meetings with qualified investors attending the conference. A live video webcast of the presentation will be available on Senti Bio's website, with a replay archived for 90 days following the event.
For more information about the conference, interested parties can visit the conference website. Additional information about Senti Bio can be found on the company's website, [Senti Bio](https://www.sentibio.com), or by following the company on X (@SentiBio) and LinkedIn (Senti Biosciences).
References:
[1] https://www.stocktitan.net/news/SNTI/senti-bio-to-present-at-the-h-c-wainwright-27th-annual-global-h01iszlz6505.html
[2] https://finance.yahoo.com/news/senti-bio-present-h-c-130500881.html
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comments
No comments yet